Nixon Peabody
Bank of America
You are here:  Home  >  Central Coast Health Watch  >  Current Article

MannKind doubles revenues from inhalable insulin Afrezza

By   /   Thursday, August 2nd, 2018  /   Comments Off on MannKind doubles revenues from inhalable insulin Afrezza

    Print       Email
MannKind reported $3.8 million in revenue from its inhalable insulin product Afrezza in the second quarter of 2018, more than double its revenue for the same period in 2017. The Westlake Village-based biotech company reported a net loss of $22.7 million, or 16 cents per share, compared to $35.3 million for the previous second quarter.…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

SB County clears path for wine tasting rooms to reopen

Read More →